180 Life Sciences – Clinical Programs Update
Returning guest, Dr. Jim Woody, CEO of 180 Life Sciences Corp., a newly formed clinical-stage biotech company focused on novel drugs for unmet needs in inflammatory diseases, fibrosis, and pain, discusses the findings of a recently completed clinical trial (Phase 2b) of the fibrosis and anti-TNF program in Dupuytren’s contracture, a fibrotic disease of the hand. The results present the potential for an earlier treatment for patients with Dupuytren’s disease, which is easy to diagnose at an early stage. Treatment with anti-TNF injections could bring long-lasting respite and prevent the disease from advancing to the stage that surgery is needed to maintain hand function.
Dr. James Woody is Chief Executive Officer at 180 Life Sciences Corp., a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. Dr. Woody has more than 25 years of pharmaceutical research and management expertise. He currently serves as Chairman of Oncomed Pharmaceuticals, where he was previously a founder and CEO, and General Partner at Latterell Venture Partners, a venture capital group focusing on early-stage healthcare companies. Dr. Woody has served in a variety of health and management roles, including as President of Roche Bioscience and CSO and Senior Vice President of R&D for Centocor. He also served as Commanding Officer and Director at the U.S. Naval Medical Research and Development Command in Bethesda, Maryland. Dr. Woody earned his M.D. from Loma Linda University and his Ph.D. in Immunology from the University of London.
